By Dean Seal
Eli Lilly has unleashed another wave of litigation against four telehealth brands in its widening legal war with sellers of alternative versions of its popular diabetes and weight-loss drugs.
The large drugmaker on Wednesday filed four lawsuits targeting Mochi Health, Fella & Delilah Health, Willow Health and Henry Meds over their sales of knockoff versions of tirzepatide, the active ingredient in its diabetes drug Mounjaro and obesity drug Zepbound.
Each of the telehealth companies are alleged by Lilly to have misled consumers and patients in their marketing of the compounded tirzepatide products and driven them away from safer medicines.
Representatives for the four companies didn't immediately respond to requests for comment.
The actions filed in California federal courts are Lilly's latest attempt to crack down on the sale of custom-made versions of its drugs, which have faced shortages due to high demand, leading to a surge of cheaper, alternative versions.
Lilly has filed lawsuits against med-spas, wellness centers and other entities for selling products that purportedly containing tirzepatide, claiming in some cases that the defendants falsely label their products as Mounjaro and Zepbound, as being the same as those drugs, as being part of Eli Lilly's clinical trials, or as being approved by federal regulators.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
April 23, 2025 10:54 ET (14:54 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.